Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.34) per share. This is unchanged from the same period last year.
Barclays Maintains Overweight on First Advantage, Lowers Price Target to $22
Barclays maintains First Advantage (NASDAQ:FA) with a Overweight and lowers the price target from $30 to $22.